Literature DB >> 19131198

Death of a female cocaine user due to the serotonin syndrome following moclobemide-venlafaxine overdose.

Małgorzata Kłys1, Piotr Kowalski, Sebastian Rojek, Adam Gross.   

Abstract

To our knowledge, the majority of evidence supporting the relationship between the serotonin syndrome and medications that effect 5HT is based on case reports. The justification for taking up this subject has been a fatal outcome of a 21 year-old female following an administration of toxic doses of moclobemide (MAOI) and venlafaxine (SNRI). As a result of complex toxicological investigations including antemortem and postmortem material, antemortem clinical observations and postmortem examinations, the cause of death was identified as overdose with antidepressants--moclobemide and venlafaxine--in the mechanism of the clinically fully developed severe toxic serotonin syndrome. The analysis of a hair strand collected from the victim documented the use of the above-mentioned drugs simultaneously with cocaine in the period of at least 20 months preceding death. The fact is a matter of considerable interest in view of the employed pharmacotherapy, giving rise to suspicion that the woman had not developed the serotonin syndrome during the almost 2-year antemortem period until she took toxic doses of both medications.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19131198     DOI: 10.1016/j.forsciint.2008.11.010

Source DB:  PubMed          Journal:  Forensic Sci Int        ISSN: 0379-0738            Impact factor:   2.395


  2 in total

1.  Serotonin syndrome with escitolapram and concomitant use of cocaine: a case report.

Authors:  Hamood Ur-Rehman Malik; Krishan Kumar
Journal:  Clin Med Insights Case Rep       Date:  2012-05-30

2.  Monitoring of adherence to headache treatments by means of hair analysis.

Authors:  Anna Ferrari; Manuela Licata; Cecilia Rustichelli; Carlo Baraldi; Daniele Vandelli; Filippo Marchesi; Federica Palazzoli; Patrizia Verri; Enrico Silingardi
Journal:  Eur J Clin Pharmacol       Date:  2016-11-20       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.